close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

291.31 +3.07 (+1.07%)
Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
MarketBeat Week in Review – 11/2 - 11/6 ↗
Via MarketBeat
News headline image
2 unpopular stocks that deserve some love and 1 facing challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
3 Dividend Kings to Buy in November and Never Sell ↗
These are arguably among the most reliable dividend payers. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Growth Stocks to Buy in November Without Any Hesitation ↗
They have both outperformed the broader equity market over the long run. 
Via The Motley Fool
AbbVie (NYSE:ABBV): A Quality Investing Candidate With Caveats ↗
Via Chartmill
AbbVie (NYSE:ABBV) Q3 2026 Results In Line With Estimates as Guidance and Dividend Rise ↗
Via Chartmill
Juvederm vs Other Dermal Fillers: What Makes It Different and Who It Is For
Via BusinesNews Wire
News headline image
AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another Test ↗
AbbVie posted Q3 revenue of $17.4 billion and raised EPS guidance as Skyrizi and Rinvoq offset Humira's decline, prompting analyst price target hikes and a stock move to fresh highs. 
Via MarketBeat
Topics Intellectual Property
News headline image
The Best Dividend Stocks to Buy With $5,000 in November ↗
AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027? ↗
AbbVie boasts faster revenue growth and stronger cash generation, while Bristol Myers trades at half the valuation multiple, a classic growth-versus-value showdown. 
Via The Motley Fool
Topics Intellectual Property
Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Lifting ↗
Via Chartmill
Topics Cannabis
News headline image
Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo ↗
AbbVie replaced one megablockbuster already. It may have found its next one. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The top 5 analyst questions from AbbVie’s Q3 earnings call
AbbVie’s third quarter was marked by a positive market reaction, attributed to robust sales growth across its immunology and neuroscience portfolios. Managem... 
Via StockStory
Topics Earnings
News headline image
AbbVie: 3 Key Takeaways for Long-Term Investors ↗
Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the dividend's long-term safety. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Is AbbVie a Buy After Its Latest Earnings Report? ↗
Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding. 
Via The Motley Fool
Topics Intellectual Property
News headline image
ABBV Q3 deep dive: Immunology and neuroscience drive growth, pipeline progress continues
Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with sales up 10.3% year on year to $17.4 billion. Its non-GAAP ... 
Via StockStory
News headline image
AbbVie (ABBV) Q3 2026 Earnings Call Transcript ↗
Skyrizi and Rinvoq drive double-digit growth as management raises full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
What AbbVie (ABBV) Said on Its Q3 Earnings Call ↗
AbbVie (NYSE:ABBV) reported third-quarter 2026 results above its guidance midpoint and raised its full-year revenue and adjusted earnings outlook, citing continued growth from its immunology and... 
Via MarketBeat
Topics Earnings
News headline image
AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates
Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non... 
Via StockStory
News headline image
AbbVie (ABBV) reports earnings tomorrow: what to expect
Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting earnings tomorrow before market open. Here’s what to expect. AbbVie beat analysts’ revenue expect... 
Via StockStory
Topics Artificial Intelligence
News headline image
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy ↗
Despite its high price relative to earnings, AbbVie remains an attractive stock. 
Via The Motley Fool
News headline image
3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach ↗
Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk. 
Via MarketBeat
News headline image
What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer ↗
They definitely matter... up to a point. 
Via The Motley Fool
Topics Bonds Economy
News headline image
Great News for AbbVie Stock Investors ↗
The company is gearing up for future major patent cliffs. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue? ↗
AbbVie's revenue lead has widened to $4 billion per quarter, but Bristol Myers shows surprising resilience despite slower growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. ↗
This pharma leader has a history of outperforming during rising interest rates. 
Via The Motley Fool
Topics Bonds Economy
News headline image
2 High-Flying Dividend Stocks to Buy and Hold for a Decade ↗
They may just be getting started. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Warren Buffett's Bluntest Warning Yet -- and 3 Stocks Built to Survive It ↗
Buffett has warned about "gambling" in the market. 
Via The Motley Fool
Topics Intellectual Property Retirement
News headline image
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. ↗
It was Griffin's biggest add for Citadel last quarter. 
Via The Motley Fool
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.